Imatinib-Induced Classical Lichen Planopilaris in Blaschko-Linear Distribution Leading to Cicatricial Alopecia

Thakran, Priyesh; Singal, Archana; Arora, Vinod

doi:10.4103/idoj.idoj_536_20

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism for cutaneous AEs is not known but there are various theories proposed like immunogenicity, changes in TKI signaling, or dose-dependent. [ 7 8 ] However, nilotinib represents an effective therapy for patients who develop intractable or severe skin reactions with imatinib as there is minimal cross-reactivity reported between the different agents of TKIs in terms of cutaneous AEs. [ 9 10 ] A similar study by Cortes et al .…”

Section: Discussionmentioning

confidence: 99%

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report

Sachdeva,

Singh,

Dayal

et al. 2023

Indian Dermatology Online Journal

View full text Add to dashboard Cite

Imatinib and nilotinib are inhibitors of tyrosine kinases (TKIs) generated from the bcr-abl fusion protein, c-Kit, and platelet-derived growth factor receptors. Cutaneous adverse effects (AEs) of TKI are the most frequent non-hematological sequelae. In our case, the common molecular target raises the possibility that cross-intolerance, in which similar AEs occur with both agents, can arise. We hereby report a rare case report on cross-intolerance of cutaneous AEs of imatinib and nilotinib in chronic myeloid leukemia.

show abstract